QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

KOD

QT74Kodiak Sciences Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
36.14
+0.43+1.20%
OverviewShort InterestFilings
KODQT74Kodiak Sciences Inc.·NASDAQ
OverviewShort InterestFilings
36.14+1.20%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand62.58M
Perf Week6.39%
Market Cap1.89BForward P/E-EPS next Y-3.12Insider Trans1.15%Shs Float-Perf Month5.00%
Enterprise Value1.88BPEG0.68EPS next Q-0.98Inst Own-Short Float-Perf Quarter59.42%
Income-197330342.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y49.77%
Sales-P/B19.71EPS next Y16.69%ROA-75.38%Short Interest-Perf YTD29.26%
Book/sh1.79P/C-EPS next 5Y-ROE-253.85%52W High47.84 -24.46%Perf Year918.03%
Cash/sh2.72P/FCF-EPS past 3/5Y-ROIC-87.69%52W Low3.43 953.64%Perf 3Y-
Dividend Est.-EV/EBITDA-9.34Sales past 3/5Y-Gross Margin0.00%Volatility4.83% 4.96%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-25.97%Oper. Margin0.00%ATR (14)2.73Perf 10Y-
Dividend Ex-Date-Quick Ratio3.54Sales Y/Y TTM-Profit Margin0.00%RSI (14)52.68Recom2.14
Dividend Gr. 3/5Y-Current Ratio3.54EPS Q/Q-11.90%SMA205.41%Beta1.54Target Price63.75
Payout0.00%Debt/Eq1.39Sales Q/Q-SMA50-7.32%Rel Volume1.73Prev Close35.71
Employees109LT Debt/Eq0.94EarningsAug 12SMA20037.05%Avg Volume696.60KPrice36.14
IPO DateOct 04, 2018Option/ShortYes / YesEPS/Sales Surpr.-1.08% -Net Debt/EBITDA0.07Volume1,205,930Change1.20%
Analyst Ratings
DateActionAnalystRatingTarget
May-11-26UpgradeChardan CapitalNeutral → Buy$18 → $61
Mar-27-26ReiteratedH.C. WainwrightBuy$38 → $58
Mar-27-26ReiteratedUBSBuy$50 → $80
Mar-26-26ReiteratedJefferiesBuy$39 → $56
Jan-22-26ReiteratedH.C. WainwrightBuy$26 → $38
Jan-07-26ReiteratedUBSNeutral$50
Nov-11-25UpgradeHC Wainwright & Co.Neutral → Buy
Oct-24-25UpgradeJP MorganNeutral → Overweight
Sep-25-25UpgradeBarclaysUnderweight → Equal Weight$17
Aug-14-25UpgradeJP MorganUnderweight → Neutral
Latest News
Jun-16-26
Jun-16-2612:09PM
Kodiak Sciences: Clinical Redemption Is Turning Into Platform LeverageSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A02726
Gross Profit0-27-26
Selling, General and Administrative Excl. Other523471
Research and Development182126206
Other Operating Expense00-26
Operating Income-234-187-277
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-4-11-17
Net Income Before Taxes-230-176-260
Income Taxes
000
Consolidated Net Income-230-176-260
Net Income From Continuing Operations-230-176-260
Net Income-230-176-260
EPS (Recurring)-4.32-3.35-4.97
EPS (Basic, Before Extraordinaries)-4.32-3.35-4.97
EPS (Diluted)-4.32-3.35-4.97
EBITDA-204-150-235
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding535352
Market Capitalization1,482——
Operating Lease Expense
———
Insider Trading Volume
$38.94$35.62$32.30$28.98$25.66● Close Price0.00M15.00M30.00M45.00M60.00MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BORGESON JOHN A.Chief Financial OfficerJun 04 '26Option Exercise1.0460,00062,400241,930Jun 05 12:00 AM
BORGESON JOHN A.Chief Financial OfficerJun 04 '26Sale34.1030,0001,023,009211,930Jun 05 12:00 AM
BORGESON JOHN A.Chief Financial OfficerApr 15 '26Option Exercise1.0457,22859,518211,930Apr 16 12:00 AM
BORGESON JOHN A.Chief Financial OfficerApr 02 '26Option Exercise1.0460,00062,400213,316Apr 02 12:00 AM
BORGESON JOHN A.Chief Financial OfficerApr 02 '26Sale39.9230,0001,197,488183,316Apr 02 12:00 AM
PERLROTH VICTORChairman and CEOMar 25 '26Option Exercise1.04600,000624,0002,395,538Mar 27 12:00 AM
BAKER BROS. ADVISORS LPdirector, 10 percent owner:Dec 18 '25Buy23.002,608,69660,000,00818,358,772Dec 19 12:00 AM
BORGESON JOHN A.See RemarksJun 17 '25Sale3.657232,640183,316Jun 17 12:00 AM
BORGESON JOHN A.See RemarksJun 15 '25Option Exercise0.003,7500184,039Jun 17 12:00 AM
BORGESON JOHN A.See RemarksJun 17 '24Sale2.752,8747,904182,164Jun 18 12:00 AM
BORGESON JOHN A.See RemarksJun 15 '24Option Exercise0.0010,9880185,038Jun 18 12:00 AM
BORGESON JOHN A.See RemarksJun 12 '24Sale2.921,5584,549179,544Jun 13 12:00 AM
BORGESON JOHN A.See RemarksJun 11 '24Option Exercise0.006,0500181,102Jun 13 12:00 AM
BORGESON JOHN A.See RemarksJun 16 '23Sale9.232,74925,373178,077Jun 16 12:00 AM
EHRLICH JASONSee RemarksJun 16 '23Sale9.232,25820,84161,924Jun 16 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR